Your request to link to rcsb for Renin

• 1HRN: high resolution crystal structures of recombinant human renin in complex with polyhydroxymonoamide inhibitors (10.1006/JMBI.1995.0372 )
• 1RNE: the crystal structure of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor (10.1016/1047-8477(91)90048-2 )
• 2BKS: crystal structure of renin-pf00074777 complex (10.1016/J.BMCL.2005.02.085 )
• 2BKT: crystal structure of renin-pf00257567 complex (10.1016/J.BMCL.2005.02.085 )
• 2FS4: ketopiperazine-based renin inhibitors: optimization of the c ring (10.1016/J.BMCL.2006.01.084 )
• 2G1N: ketopiperazine-based renin inhibitors: optimization of the "c" ring (10.1016/J.BMCL.2006.01.084 )
• 2G1O: ketopiperazine-based renin inhibitors: optimization of the "c" ring (10.1016/J.BMCL.2006.01.084 )
• 2G1R: ketopiperazine-based renin inhibitors: optimization of the c ring (10.1016/J.BMCL.2006.01.084 )
• 2G1S: ketopiperazine-based renin inhibitors: optimization of the c ring (10.1016/J.BMCL.2006.01.084 )
• 2G1Y: ketopiperazine-based renin inhibitors: optimization of the "c" ring (10.1016/J.BMCL.2006.01.084 )
• 2G20: ketopiperazine-based renin inhibitors: optimization of the c ring (10.1016/J.BMCL.2006.01.084 )
• 2G21: ketopiperazine-based renin inhibitors: optimization of the "c" ring (10.1016/J.BMCL.2006.01.084 )
• 2G22: ketopiperazine-based renin inhibitors: optimization of the "c" ring (10.1016/J.BMCL.2006.01.084 )
• 2G24: ketopiperazine-based renin inhibitors: optimization of the "c" ring (10.1016/J.BMCL.2006.01.084 )
• 2G26: ketopiperazine-based renin inhibitors: optimization of the "c" ring (10.1016/J.BMCL.2006.01.084 )
• 2G27: ketopiperazine-based renin inhibitors: optimization of the "c" ring (10.1016/J.BMCL.2006.01.084 )
• 2I4Q: human renin/pf02342674 complex (10.1016/J.BMC.2007.05.069 )
• 2IKO: crystal structure of human renin complexed with inhibitor (10.1016/J.AB.2006.10.017 )
• 2IKU: crystal structure of human renin complexed with inhibitors (10.1016/J.AB.2006.10.017 )
• 2IL2: crystal structure of human renin complexed with inhibitor (10.1016/J.AB.2006.10.017 )
• 2REN: structure of recombinant human renin, a target for cardiovascular- active drugs, at 2.5 angstroms resolution
• 2V0Z: crystal structure of renin with inhibitor 10 (aliskiren) (10.1016/S1074-5521(00)00134-4 )
• 2V10: crystal structure of renin with inhibitor 9 (10.1016/S1074-5521(00)00134-4 )
• 2V11: crystal structure of renin with inhibitor 6 (10.1016/S1074-5521(00)00134-4 )
• 2V12: crystal structure of renin with inhibitor 8 (10.1016/S1074-5521(00)00134-4 )
• 2V13: crystal structure of renin with inhibitor 7 (10.1016/S1074-5521(00)00134-4 )
• 2V16: crystal structure of renin with inhibitor 3 (10.1016/S1074-5521(00)00134-4 )
• 2X0B: crystal structure of human angiotensinogen complexed with renin (10.1038/NATURE09505 )
• 3D91: human renin in complex with remikiren
• 3G6Z: design and preparation of potent, non-peptidic, bioavailable renin inhibitors (10.1021/JM900022F )
• 3G70: design and preparation of potent, non-peptidic, bioavailable renin inhibitors (10.1021/JM900022F )
• 3G72: design and preparation of potent, non-peptidic, bioavailable renin inhibitors (10.1021/JM900022F )
• 3GW5: crystal structure of human renin complexed with a novel inhibitor (10.1016/J.BMCL.2009.04.140 )
• 3K1W: new classes of potent and bioavailable human renin inhibitors (10.1016/J.BMCL.2009.09.104 )
• 3KM4: optimization of orally bioavailable alkyl amine renin inhibitors (10.1016/J.BMCL.2009.11.066 )
• 3O9L: design and optimisation of new piperidines as renin inhibitors (10.1016/J.BMCL.2010.08.086 )
• 3OAD: design and optimization of new piperidines as renin inhibitors (10.1016/J.BMCL.2010.08.086 )
• 3OAG: design and optimization of new piperidines as renin inhibitors (10.1016/J.BMCL.2010.08.086 )
• 3OOT: crystal structure analysis of renin-indole-piperazin inhibitor complexes (10.1016/J.BMCL.2010.08.092 )
• 3OQF: crystal structure analysis of renin-indole-piperazine inhibitor complexes (10.1016/J.BMCL.2010.08.092 )
• 3OQK: crystal structure analysis of renin-indole-piperazin inhibitor complexes (10.1016/J.BMCL.2010.08.092 )
• 3OWN: potent macrocyclic renin inhibitors (10.1016/J.BMCL.2010.10.140 )
• 3Q3T: alkyl amine renin inhibitors: filling s1 from s3 (10.1016/J.BMCL.2011.06.043 )
• 3Q4B: clinically useful alkyl amine renin inhibitors (10.1021/ML200137X )
• 3Q5H: clinically useful alkyl amine renin inhibitors (10.1021/ML200137X )
• 3SFC: structure-based optimization of potent 4- and 6-azaindole-3- carboxamides as renin inhibitors (10.1016/J.BMCL.2011.06.114 )
• 3VCM: crystal structure of human prorenin (10.1016/J.JMB.2012.05.003 )
• 3VSW: human renin in complex with compound 8 (10.1016/J.BMCL.2012.05.092 )
• 3VSX: human renin in complex with compound 18 (10.1016/J.BMCL.2012.05.092 )
• 3VUC: human renin in complex with compound 5 (10.1021/ML300168E )
• 3VYD: human renin in complex with inhibitor 6 (10.1016/J.BMCL.2012.09.103 )
• 3VYE: human renin in complex with inhibitor 7 (10.1016/J.BMCL.2012.09.103 )
• 3VYF: human renin in complex with inhibitor 9 (10.1016/J.BMCL.2012.09.103 )
• 4AMT: crystal structure at 2.6a of human prorenin
• 4GJ5: crystal structure of renin in complex with nvp-amq838 (compound 5) (10.1021/JM3017078 )
• 4GJ6: crystal structure of renin in complex with nvp-ayz832 (compound 6a) (10.1021/JM3017078 )
• 4GJ7: crystal structure of renin in complex with nvp-bca079 (compound 12a) (10.1021/JM3017078 )
• 4GJ8: crystal structure of renin in complex with pkf909-724 (compound 3) (10.1021/JM301706J )
• 4GJ9: crystal structure of renin in complex with gp055321 (compound 4) (10.1021/JM301706J )
• 4GJA: crystal structure of renin in complex with nvp-ayl747 (compound 5) (10.1021/JM301706J )
• 4GJB: crystal structure of renin in complex with nvp-bbv031 (compound 6) (10.1021/JM301706J )
• 4GJC: crystal structure of renin in complex with nvp-bch965 (compound 9) (10.1021/JM301706J )
• 4GJD: crystal structure of renin in complex with nvp-bgq311 (compound 12) (10.1021/JM301706J )
• 4PYV: crystal structure of renin in complex with compound4 (10.1021/ML500137B )
• 4Q1N: structure-based design of 4-hydroxy-3,5-substituted piperidines as direct renin inhibitors (10.1021/ML500137B )
• 4RYC: renin in complexed with 4-methoxy-3-(3-methoxypropoxy)-n-{[(3s,4s)-4- {[(4-methylphenyl)sulfonyl]amino}pyrrolidin-3-yl]methyl}-n-(propan-2- yl)benzamide inhibitor (10.1016/J.BMCL.2015.02.039 )
• 4RYG: renin in complexed with n-({(3s,4s)-4-[(benzylsulfonyl) amino]pyrrolidin-3-yl}methyl)-4-methoxy-3-(3-methoxypropoxy)-n- (propan-2-yl)benzamide inhibitor (10.1016/J.BMCL.2015.02.039 )
• 4RZ1: renin in complexed with (3s,4s)-4-({[4-methoxy-3-(3-methoxypropoxy) benzoyl](propan-2-yl)amino}methyl)pyrrolidin-3-yl benzylcarbamate inhibitor (10.1016/J.BMCL.2015.02.040 )
• 4S1G: renin in complex with (s)-1-(3-fluoro-5-(((s)-1-phenylethyl) carbamoyl)benzyl)-4-isopropyl-4-methyl-6-oxotetrahydropyrimidin- 2(1h)-iminium 21-feb-18 4s1g 1 title (10.1016/J.BMCL.2015.02.003 )
• 4XX3: renin in complex with (s)-1-(3-(benzylcarbamoyl)benzyl)-4-isopropyl-4- methyl-6-oxotetrahydropyrimidin-2(1h)-iminium (10.1016/J.BMCL.2015.02.003 )
• 4XX4: renin in complex with (4s)-4-isopropyl-4-methyl-6-oxo-1-(3-(2-oxo-4- phenylpyrrolidin-1-yl)benzyl)tetrahydropyrimidin-2(1h)-iminium (10.1016/J.BMCL.2015.02.003 )
• 5KOQ: discovery of tak-272: a novel, potent and orally active renin in- hibitor (10.1016/J.BMC.2016.09.030 )
• 5KOS: discovery of tak-272: a novel, potent and orally active renin in- hibitor (10.1021/ACSMEDCHEMLETT.6B00251 )
• 5KOT: discovery of tak-272: a novel, potent and orally active renin in- hibitor
• 5SXN: structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors (10.1016/J.BMC.2016.09.030 )
• 5SY2: structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors (10.1016/J.BMC.2016.09.030 )
• 5SY3: structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors (10.1016/J.BMC.2016.09.030 )
• 5SZ9: structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors (10.1016/J.BMC.2016.09.030 )
• 5T4S: novel approach of fragment-based lead discovery applied to renin inhibitors (10.1016/J.BMC.2016.09.065 )
• 5TMG: optimization of 3,5-disubstitued piperidine: discovery of non-peptide mimetics as an orally active renin inhibitor
• 5TMK: optimization of 3,5-disubstitued piperidine: discovery of non-peptide mimetics as an orally active renin inhibitor
• 5V8V: crystal structure of human renin in complex with a biphenylpipderidinylcarbinol (10.1016/J.BMCL.2017.09.046 )
• 5VPM: crystal structure of human renin in complex with a biphenylpipderidinylcarbinol (10.1016/J.BMCL.2017.09.046 )
• 5VRP: crystal structure of human renin in complex with a biphenylpipderidinylcarbinol (10.1016/J.BMCL.2017.09.046 )
• 6I3F: crystal structure of the complex of human angiotensinogen and renin at 2.55 angstrom (10.1074/JBC.RA118.006608 )